Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.75 |
| ▸ | ESR1 | P03372 | 6/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | ATM | Q13315 | 2/20 | 0.75 |
| ▸ | PGR | P06401 | 2/20 | 0.75 |
| ▸ | AR | P10275 | 2/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.72 |
| ▸ | SHBG | P04278 | 2/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | FYN | P06241 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180361 | 1.00 | LMNA (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL7633202 | 0.94 | LMNA (0.73) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL9404736 | 0.91 | LMNA (0.77) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL28077837 | 0.91 | ESR1 (0.77) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL4333126 | 0.91 | LMNA (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL40564 | 0.91 | LMNA (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL11102416 | 0.91 | LMNA (0.75) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL547293 | 0.89 | LMNA (0.80) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL2313094 | 0.89 | LMNA (0.73) | LMNAESR1SMN1; SMN2ADORA3ATM | |
| SCHEMBL24102647 | 0.89 | LMNA (0.81) | LMNAESR1SMN1; SMN2ADORA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2062569-B1 | Vaginal delivery system | BAYER OY (FI) | 2011-05-11 | — | — | EP | claimed |
| WO-2010133757-A1 | VAGINAL DELIVERY SYSTEM | BAYER SCHERING PHARMA OY (FI) | 2010-11-25 | — | — | WO | claimed |
| US-20100285097-A1 | VAGINAL DELIVERY SYSTEM | BAYER OY (FI) | 2010-11-11 | — | — | US | claimed |
| CN-101873850-A | Vaginal delivery system | BAYER SCHERING PHARMA OY | 2010-10-27 | — | — | CN | claimed |
| EP-2227220-A1 | VAGINAL DELIVERY SYSTEM | Bayer Schering Pharma Oy (FI) | 2010-09-15 | — | — | EP | claimed |
| US-20090142313-A1 | VAGINAL DELIVERY SYSTEM | BAYER SCHERING PHARMA OY (FI) | 2009-06-04 | — | — | US | claimed |
| WO-2009066006-A1 | VAGINAL DELIVERY SYSTEM | BAYER SCHERING PHARMA OY (FI) | 2009-05-28 | — | — | WO | claimed |
| EP-2062568-A1 | Vaginal delivery system | Bayer Schering Pharma Oy (FI) | 2009-05-27 | — | — | EP | claimed |
| EP-2062569-A1 | Vaginal delivery system | Bayer Schering Pharma Oy (FI) | 2009-05-27 | — | — | EP | claimed |
| US-20080279915-A1 | Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen | HEXAL AG (DE) | 2008-11-13 | — | — | US | claimed |
| US-20210361920-A1 | Drug Delivery Device and System with Metered Dosing for Semi-Solid Compositions | Compounding Innovations LLC (US) | 2021-11-25 | — | — | US | disclosed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| EP-2062569-B1 | Vaginal delivery system | BAYER OY (FI) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010133757-A1 | VAGINAL DELIVERY SYSTEM | BAYER SCHERING PHARMA OY (FI) | 2010-11-25 | — | — | WO | disclosed |
| US-20090142313-A1 | VAGINAL DELIVERY SYSTEM | BAYER SCHERING PHARMA OY (FI) | 2009-06-04 | — | — | US | disclosed |
| WO-2009066006-A1 | VAGINAL DELIVERY SYSTEM | BAYER SCHERING PHARMA OY (FI) | 2009-05-28 | — | — | WO | disclosed |
| EP-2062568-A1 | Vaginal delivery system | Bayer Schering Pharma Oy (FI) | 2009-05-27 | — | — | EP | disclosed |
| EP-2062569-A1 | Vaginal delivery system | Bayer Schering Pharma Oy (FI) | 2009-05-27 | — | — | EP | disclosed |
| US-20080279915-A1 | Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen | HEXAL AG (DE) | 2008-11-13 | — | — | US | disclosed |